Krystexxa Market Report 2026

Krystexxa Market Overview

• The Krystexxa market growth in the historic period has been driven by limitations of conventional gout therapies, increasing prevalence of chronic gout • Market expansion is supported by growing refractory gout patient pool, increased referral to specialty clinics • Growth Driver: Rising Gout Incidence Driving Growth In Krystexxa Market • Market Trend: Innovative Advancing Immune-Modulating Therapies for Uncontrolled Gout • North America was the largest region and fastest growing region.

What Is Covered Under Krystexxa Market?

Krystexxa (pegloticase) is a medication used to treat chronic gout in patients who are refractory to conventional therapies. It is an intravenous infusion that works by breaking down uric acid, thereby reducing uric acid levels in the body, which can help prevent gout attacks and related complications. The main formulations in the krystexxa market are injectable formulation (lyophilized powder) and ready-to-use solutions. Krystexxa's injectable formulation, which is a lyophilized powder, refers to a freeze-dried form of the drug that is reconstituted with a diluent before administration. The various indications include treatment of chronic gout, management of hyperuricemia in gout patients, and treatment of refractory gout, and several patient demographics including adult patients, elderly patients and patients with comorbid conditions. Distribution channels for these treatments include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, rheumatology practices, and home healthcare providers.

What Is The Krystexxa Market Growth Forecast?

The growth in the forecast period can be attributed to growing refractory gout patient pool, increased referral to specialty clinics, expansion of infusion services, supportive reimbursement for biologics, continued unmet need in severe gout. Major trends in the forecast period include growth in biologic therapies for refractory gout, focus on uric acid lowering enzyme treatments, specialty management of chronic gout patients, expansion of infusion based rheumatology care, rising use in severe and treatment resistant cases.

What Is The Driver Of The Krystexxa Market?

The increasing incidence of gout disease is expected to propel the growth of the Krystexxa market going forward. Gout disease refers to a type of arthritis caused by the buildup of uric acid crystals in the joints, leading to inflammation, pain, and swelling. The increased incidence of gout disease is attributed to factors such as poor dietary habits, obesity, aging, certain medications, genetics, chronic kidney disease, a sedentary lifestyle, and comorbid conditions like high blood pressure and diabetes. Krystexxa (pegloticase) helps gout patients by lowering uric acid levels in the blood, specifically targeting chronic gout that is resistant to conventional treatments, thereby reducing the frequency and severity of gout flare-ups and providing relief from the painful symptoms associated with this condition. For instance, in June 2024, according to Rheumatology and Therapy, a US-based international peer-reviewed medical journal, the prevalence of comorbid gout and chronic kidney disease in the United States was projected to increase from 7.9 million in 2023 to 8.6 million in 2027, then to 9.2 million in 2031, and reaching 9.6 million in 2035, representing a 29% increase from 2023 to 2035. Therefore, the increasing incidence of gout disease is driving the krystexxa industry.

Key Players In The Global Krystexxa Market

Major companies operating in the krystexxa market are Amgen Inc.

Global Krystexxa Market Trends and Insights

Key trend in the krystexxa market is focusing on advancement of immunomodulatory strategies such as rheumatology research dissemination initiative to enhance clinical evidence visibility, support informed therapeutic decision-making, and strengthen stakeholder understanding of emerging advancements in inflammatory and autoimmune disease management. Rheumatology research dissemination initiative refers to a structured scientific communication effort aimed at presenting, sharing, and promoting new clinical findings, therapeutic data, and investigational insights within the field of rheumatology. For instance, in June 2024, Amgen Inc., a US-based biotechnology company, presented innovative rheumatology research at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, highlighting new clinical data related to Krystexxa (pegloticase). The research showcased expanded evidence on treatment response patterns, patient-reported outcomes, and immunologic behavior when using advanced therapeutic combinations. Krystexxa, a PEGylated uricase enzyme therapy, continues to demonstrate unique clinical benefits for adults with uncontrolled chronic gout by leveraging precision immune modulation to improve efficacy and manage anti-drug antibody formation. These new insights presented by Amgen reinforce Krystexxa’s role as a leading biologic option for patients with severe gout who have not responded adequately to conventional therapies.

What Are Latest Mergers And Acquisitions In The Krystexxa Market?

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. With the acquisition of Horizon Therapeutics, Amgen Inc. aims to significantly strengthen its position in the rare disease and inflammation market. Horizon Therapeutics Plc is an Ireland-based biopharmaceutical company that specializes in providing Krystexxa.

What Defines the Krystexxa Market?

The krystexxa market consists of sales of pegloticase and infusion kits sales. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Krystexxa Market Report 2026?

The krystexxa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the krystexxa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.